BerandaNB3 • FRA
add
Neurocrine Biosciences Inc
Tutup sebelumnya
€109,00
Rentang hari
€110,00 - €110,00
Rentang tahun
€100,85 - €147,45
Kapitalisasi pasar
12,14Â M USD
Volume Rata-Rata
31,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 627,70Â jt | 21,84% |
Biaya operasional | 301,80Â jt | 37,87% |
Laba bersih | 103,10Â jt | -30,20% |
Margin laba bersih | 16,43 | -42,69% |
Penghasilan per saham | 1,69 | 9,74% |
EBITDA | 138,10Â jt | -11,47% |
Tarif pajak efektif | 36,59% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,08Â M | 4,31% |
Total aset | 3,72Â M | 14,37% |
Total liabilitas | 1,13Â M | 10,75% |
Total ekuitas | 2,59 M | — |
Saham yang beredar | 99,70 jt | — |
Harga terhadap nilai buku | 4,18 | — |
Tingkat pengembalian aset | 9,03% | — |
Tingkat pengembalian modal | 10,75% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 103,10Â jt | -30,20% |
Kas dari operasi | 242,50Â jt | 96,36% |
Kas dari investasi | -68,30Â jt | 66,15% |
Kas dari pembiayaan | -290,00Â jt | -919,21% |
Perubahan kas bersih | -116,10Â jt | -172,54% |
Arus kas bebas | 220,28Â jt | 138,04% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.800
